# US 2016/0257930 A1 · Neuronal stem cell differentiation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0257930 A1
- Document ID: US20160257930A1
- Status: Published application
- Kind: A1
- Application number: 15/029,164
- Filed: 2014-10-13
- Published: 2016-09-08
- Earliest claimed: 2013-10-14
- Inventors: Paul Kemp; Nicholas Allen
- Web page: https://patentgrep.com/patent/US20160257930A1

## CPC

- C12N 5/0619: {Neurons}
- C12N 2500/14: Calcium; Ca chelators; Calcitonin
- C12N 2500/38: Vitamins
- C12N 2501/01: Modulators of cAMP or cGMP, e.g. non-hydrolysable analogs, phosphodiesterase inhibitors, cholera toxin
- C12N 2501/13: Nerve growth factor [NGF]; Brain-derived neurotrophic factor [BDNF]; Cilliary neurotrophic factor [CNTF]; Glial-derived neurotrophic factor [GDNF]; Neurotrophins [NT]; Neuregulins
- C12N 2501/40: Regulators of development
- C12N 2501/415: Wnt; Frizzeled
- C12N 2501/42: Notch; Delta; Jagged; Serrate
- C12N 2501/845: Gamma amino butyric acid [GABA]
- C12N 2501/999: Small molecules not provided for elsewhere
- C12N 2506/08: from cells of the nervous system
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The invention relates to at least one novel neural cell differentiation medium for the production of neural cells from at least one precursor cell capable of lineage specific differentiation; a method for neural cell differentiation using said medium; the use of said medium and said method for lineage specific differentiation of at least one precursor cell towards a neural cell fate; and a kit of parts comprising said at least one said neural cell differentiation medium.

## Claims

### Claim 1

A neural cell differentiation medium for the production of neural cells from at least one precursor cell capable of lineage specific differentiation, comprising:
i) at least one cell culture base medium;
ii) at least one serum-free supplement for neural cell culture;
iii) a cell-cycle inhibitor;
iv) at least one Tropomyosin receptor kinase B [TrkB] receptor agonist;
v) a canonical Wnt pathway agonist;
vi) ascorbic Acid or vitamin C or a salt or derivative thereof; and
vii) a solution of calcium ions.

### Claim 2 (depends on 1)

The neural cell differentiation medium according to claim 1 further comprising at least any one or more of the following, including all combinations thereof:
viii) a notch signaling inhibitor;
ix) a CREB (cAMP response element-binding protein) activator;
x) a γ-aminobutyric acid (GABA) receptor agonist; and
xi) a non-canonical WNT pathway agonist.

### Claim 3 (depends on 1)

The neural differentiation medium according to claim 1 wherein said cell culture base medium is selected from the group consisting of: DMEM and DMEM:F12.

### Claim 4 (depends on 1)

The neural differentiation medium according to claim 1 wherein said serum free supplement is selected from the group consisting of: N2 supplement, B27 supplement, glutamine supplement, and NeuroBrew™.

### Claim 5 (depends on 1)

The neural differentiation medium according to claim 1 wherein said cycle inhibitor is an inhibitor of the G1/S cell checkpoint.

### Claim 6 (depends on 5)

The neural differentiation medium according to claim 5 wherein said cell cycle inhibitor is selected from the group consisting of: PD0332991, AZD5438, Baicalein, CI 898 trihydrochloride, Daidzein, WYE 687 dihydrochloride, YC 1, flavopiridol, indisulam, purvalanol, seliciclib, mimosine, and purvalanol.

### Claim 7 (depends on 1)

The neural differentiation medium according to claim 1 wherein said Tropomyosin receptor kinase B [TrkB] receptor agonist is Brain Derived Neurotrophic Factor (BDNF), neurotrophin-4 (NT-4), Glial cell-derived neurotrophic factor (GDNF), neurotrophin-3 (NT-3), or an analogue thereof.

### Claim 8 (depends on 7)

The neural differentiation medium according to claim 7 wherein said Tropomyosin receptor kinase B [TrkB] receptor agonist is selected from the group consisting of: 7,8-dihydroxyflavone, N,N′,N″Tris(2-hydroxyethyl)-1,3,5-ben-zenetricarboxamide (LM22A4), and 4′-dimethylamino-7,8-dihydroxyflavone.

### Claim 9 (depends on 1)

The neural differentiation medium according to claim 1 wherein said canonical Wnt pathway agonist is a Glycogen synthase kinase 3 beta (GSK3β) inhibitor.

### Claim 10 (depends on 9)

The neural differentiation medium according to claim 9 wherein said canonical Wnt pathway agonist is selected from the group consisting of: CHIR99021, (2′Z,3′E)-6-Bromoindirubin-3′-oxime (BIO), (2′Z,3′E)-6-Bromoindirubin-3′-acetoxime (BIO-acetoxime), 5-Ethyl-7,8-dimethoxy-1H-pyrrolo[3,-4-c]isoquinoline-1,3(2H)-dione (3F8), 1-(7-Methoxyquinolin-4-yl)-3-[6-(tr-ifluoromethyl)pyridin-2-yl]urea (A1070722), N-[(4-Methoxyphenyl)methyl]-N′-(5-ni-tro-2-thiazolyl)urea (AR-A 014418), 3-(2,4-Dichlorophenyl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione (SB216763), 3-[(3-Chloro-4-hydroxyphenyl)amino]-4-(2-nitrophenyl)-1H-pyrrole-2,5-dione (SB415286), N-(3-Chloro-4-methylphenyl)-5-(4-ni-trophenyl)-1,3,4-oxadiazol-2-amine (TC-G24), 2-Methyl-5-[3-[4-(methylsulfinyl)ph-enyl]-5-benzofuranyl]-1,3,4-oxadiazole (TCS2002), and 3-[[6-(3-Aminophenyl)-7H-pyrrolo[2,-3-d]pyrimidin-4-yl]oxyphenol ditrifluoroacetate (TWS 119).

### Claim 11 (depends on 2)

The neural differentiation medium according to claim 2 wherein said notch signaling inhibitor is a γ-secretase inhibitor.

### Claim 12 (depends on 11)

The neural differentiation medium according to claim 11 wherein said notch signaling inhibitor is selected from the group consisting of: N-[N-(3,5-Difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester (DAPT), Semagacestat, BMS-299897, BMS-708163, dibenzazepine, MK-0752, RO4929097, LY900009, LY3039478, LY411575, MRK-003, MRK-006, and BMS-906024.

### Claim 13 (depends on 2)

The neural differentiation medium according to claim 2 wherein said CREB activator is selected from the group consisting of: an adenylyl cyclase activator, cAMP or an analogue thereof, and a phosphodiesterase inhibitor.

### Claim 14 (depends on 13)

The neural differentiation media according to claim 13 wherein said adenylyl cyclase activator is selected from the group consisting of: forskolin, N,N-Dimethyl-(3R,4aR,5S,6aS,10S,10a-R,10bS)-5-(acetyloxy)-3-ethenyldodecahydro-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-1H-naphth-o[2,1-b]pyran-6-yl ester β-alanine hydrochloride, Pituitary Adenylate Cyclase-Activating Polypeptide 1-27, 1,9-Dideoxyforskolin, 5-[[2-(6-Amino-9H-purin-9-yl)ethyl]amino]-1-pentanol, and Colforsin dapropate hydrochloride.

### Claim 15 (depends on 13)

The neural differentiation medium according to claim 13 wherein said cAMP analogue is selected from the group consisting of: Dibutyryl-cAMP, 8-(4-Chlorophenylthio)-2′-O-methylad-enosine-3′,5′-cyclic monophosphate acetoxymethyl ester, 8-Bromo-cAMP, and (S)-Adenosine, cyclic 3′,5′-(hydrogenphosphorothioate) triethylammonium.

### Claim 16 (depends on 13)

The neural differentiation medium according to claim 13 wherein said phosphodiesterase inhibitor is selected from the group consisting of: CGH 2466 dihydrochloride, Cilostamide, Cilostazol, 5-[3-[(1S,2S,4R)-Bicyclo[2.2.1]hept-2-yloxy]-4-methoxyphenyl]tetrahydro-2(1H)-pyrimid-inone, Dipyridamole, EHNA hydrochloride, Enoximone, Etazolate hydrochloride, Gisadenafil besylate, MDL 12330A hydrochloride, Mesopram, Rolipram, Pentoxifylline, Anagrelide hydrochloride, N,N,2-Trimethyl-5-nitro-benzenesulf-onamide, 4-[(2R)-2-[3-(Cyclopentyloxy)-4-met-hoxyphenyl]-2-phenylethyl]-pyridine hydrochloride, Vinpocetine, Zaprinast, and Zardaverine.

### Claim 17 (depends on 2)

The neural differentiation medium according to claim 2 wherein said γ-aminobutyric acid (GABA) receptor agonist is selected from the group consisting of: recombinant γ-aminobutyric acid (GABA), Calcium acetylhomotaurinate, 1-(4-Aminobutanoyl)-4-[1,3-bis(dihy-droxyphosphoryloxy)propan-2-yloxy]-7-nitroindoline-, Isoguvacine hydrochloride, 3-(2,5-Difluorophenyl)-7-(1,1-dimet-hylethyl)-6-[(1-methyl-1H-1,2,4-triazol-5-yl)metho-xy]-1,2,4-triazolo[4,3-b]pyridazine, MK0343, MRK 016, Muscimol, trans-4-Aminocrotonic acid, 5-Nitro-α-oxo-N-(1R)-phenylethyl]-1H-indole-3-acetamide, 2′,4-Difluoro-5′-[8-fluoro-7-(1-hydro-xy-1-methylethyl)imidazo[1,2-a]-pyridin-3-yl]-[1,1-′-biphenyl]-2-carbonitrile, and (Z)-3-[(Aminoiminomethyl)thio]prop-2-enoic acid sulfate.

### Claim 18 (depends on 2)

The neural differentiation medium according to claim 2 wherein said non-canonical Wnt pathway agonist is a Protein Kinase C (PKC) activator.

### Claim 19 (depends on 18)

The neural differentiation medium according to claim 18 wherein said non-canonical Wnt pathway agonist is selected from the group consisting of: Phorbol 12-myristate 13-acetate (PMA), Phorbol 12,13-dibutyrate, cholesterol sulphate, Bryostatin 1, 2-[(2-Pentylcyclopropyl)methyl]cycl-opropaneoctanoic acid (FR 236924), (2S,5S)-1,2,4,5,6,8-Hexahydro-5-(hy-droxymethyl)-1-methyl-2-(1-methylethyl)-3H-pyrrolo-[4,3,2-gh]-1,4-benzodiazonin-3-one, Ingenol 3-angelate, and 5-Chloro-N-heptylnaphthalene-1-sulf-onamide, 5-Chloro-N-(6-phenylhexyl)-1-naphth-alenesulfonamide.

### Claim 20 (depends on 1)

The neural differentiation medium according to claim 1 wherein any one or more of iii)-v) is a small molecule compound or an isolated or recombinant peptide, protein or antibody.

### Claim 21 (depends on 1)

The neural differentiation medium according to claim 1 wherein said solution of chemical ions is calcium chloride.

### Claim 22 (depends on 1)

An ex vivo culture medium comprising the neural differentiation medium according to claim 1.

### Claim 23 (depends on 2)

An ex vivo culture medium comprising the neural differentiation medium according to claim 2.

### Claim 24 (depends on 1)

A method for neural cell differentiation comprising: culturing in a culture medium at least one precursor cell capable of lineage specific differentiation wherein said culture medium comprises a neural cell differentiation media according to claim 1 and following culture in said medium said precursor cell develops into a neural cell.

### Claim 25 (depends on 24)

The method according to claim 24 wherein said precursor cell is selected from the group consisting of: stem cells; pluripotent or multipotent progenitor cells; embryonic stem cells (ESC); induced pluripotent stem cells (iPSC); adult stem cells; somatic stem cells; cancer stem cells; and any cell capable of lineage specific differentiation into a neural cell.

### Claim 26 (depends on 24)

The method according to claim 24 wherein said neural cell is selected from the group comprising: any cell type classified as part of the nervous system; neurones; astrocytes; and glial cells.

### Claim 27 (depends on 2, 24)

The method according to claim 24 wherein said method comprises:
culturing said cell(s) in a first neural cell differentiation medium according to claim 2 wherein said medium comprises or consist of i-x;
followed by culturing said cell(s) in a second neural cell differentiation medium according to claim 2 wherein said medium comprises or consist of i-vii and xi.

### Claim 28 (depends on 27)

The method according to claim 27 wherein said method comprises culturing said cell(s) in said first neural cell differentiation medium for a number of days selected from the group consisting of the following days 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 and 20 days.

### Claim 29 (depends on 27)

The method according to claim 27 wherein said method comprises culturing said cell(s) in said second neural cell differentiation medium for a number of days selected from the group consisting of the following days 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 and 30 days.

### Claim at position 30

-31. (canceled)

### Claim 32

A kit for the differentiation of at least one precursor cell capable of lineage specific differentiation into a neural cell comprising:
a. a neural cell differentiation medium comprising:
i. at least one cell culture base medium;
ii. at least one serum-free supplement for neural cell culture;
iii. a cell-cycle inhibitor;
iv. at least one Tropomyosin receptor kinase B [TrkB] receptor agonist;
v. a canonical Wnt pathway agonist;
vi. ascorbic acid or vitamin C or a salt or derivative thereof;
vii. a solution of calcium ions;
viii. a notch signaling inhibitor;
ix. a CREB (cAMP response element-binding protein) activator;
x. a γ-aminobutyric acid (GABA) receptor agonist;
b. a neural cell differentiation medium comprising:
i. at least one cell culture base medium;
ii. at least one serum-free supplement for neural cell culture;
iii. a cell-cycle inhibitor;
iv. at least one Tropomyosin receptor kinase B [TrkB] receptor agonist;
v. a canonical Wnt pathway agonist;
vi. ascorbic acid or vitamin C or a salt or derivative thereof;
vii. a solution of calcium ions; and
xi) a non-canonical WNT pathway agonist; and
optionally, reagents and instructions pertaining to the use of said neural differentiation mediums.

### Claim 33 (depends on 2)

The neural differentiation medium according to claim 2 wherein any one or more of viii)-xi) is a small molecule compound or an isolated or recombinant peptide, protein or antibody.
